Search results for "cardiovascular prevention"

showing 10 items of 25 documents

Low-density-lipoproteins size and cardiovascular prevention

2005

Low-density lipoprotein (LDL) size appears to be an important predictor of cardiovascular events and progression of coronary artery disease, and the predominance of small, dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Yet, other authors have suggested that LDL subclass measurement does not add independent information to that conferred generically by LDL concentration and other standard risk factors. Therefore, the debate continues as to whether to measure LDL particle size for cardiovascular prevention and, if so, in which categories of patients. Since the therapeutic modulation of distinct LDL …

Small dense ldlmedicine.medical_specialtyFramingham Risk Scorebusiness.industryPreventionSmall dense LDLmedicine.diseaseCoronary artery diseaseCoronary heart diseasechemistry.chemical_compoundchemistryCardiovascular preventionRisk factorsLow-density lipoproteinInternal medicineAtherosclerosiInternal MedicinemedicineCardiologylipids (amino acids peptides and proteins)Risk factorbusinessNational Cholesterol Education ProgramLipoprotein
researchProduct

New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors

2011

Microsomal triglyceride transfer protein (MTP) is involved in the synthesis of very low density lipoprotein in the liver. Its deficiency results in abetalipoproteinemia. MTP inhibitors target the assembly and secretion of apolipoprotein B-containing lipoproteins. These agents may potentially play a role, alone or in combination, in the treatment of hypercholesterolemia or hypertriglyceridemia. Clinical applications of MTP inhibitors initially focused primarily on high-dose monotherapy in order to produce substantial reductions in LDL-cholesterol levels but these proved to induce significant hepatic steatosis and transaminase elevations. However, likely orphan indications for MTP inhibitors,…

Very low-density lipoproteinApolipoprotein BHypercholesterolemiaFamilial hypercholesterolemiaLipoproteins VLDLPharmacologyMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundMicrosomesDrug DiscoveryClinical endpointHumansMedicineApolipoproteins BHypertriglyceridemiaPharmacologybiologybusiness.industryCholesterolAbetalipoproteinemiamedicine.diseaseAbetalipoproteinemiaBiochemistrychemistryMTP-inhibitors lipids lipoproteins atherosclerosis cardiovascular prevention.biology.proteinlipids (amino acids peptides and proteins)SteatosisCarrier ProteinsbusinessCurrent Pharmaceutical Design
researchProduct

Myocardial infarction in Young adults: risk factors, clinical characteristics and prognosis according to our experience

2013

Objectives. Myocardial infarction is a relatively unusual phenomenon in young subjects. The aim if this work is to characterize the risk profile and factors influencing outcomes of these patients since it makes possible to manage prevention interventions. Patients and Methods. We examined cardiovascular risk factors, clinical presentation, angiographic picture and outcome of a group of young patients hospitalized for a myocardial infarction. We enrolled 121 young patients consecutively admitted to our hospital for a myocardial infarction and examined them not only at the initial stage, but also after 3 months and one year; finally a long-term telephonic follow up was performed, when possibl…

cardiovascular prevention cardiovascular risk factors coronary artery disease ischemic heart disease myocardial infarction young adults
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Vascular Changes and Aging

1998

The progress of cardiovascular prevention and the large use of antibiotics have determined in the last fifty years a progressive increase of life duration, especially in the western countries, and so, a noticeable increase of elderly subjects in the population (1,2).

education.field_of_studymedicine.medical_specialtybusiness.industrymedicine.drug_classPopulationAntibioticsBlood pressurePhysiological AgingCardiovascular preventionInternal medicineCardiologyMedicinebusinesseducation
researchProduct

Role of Nutraceuticals in Hypolipidemic Therapy.

2015

Nutraceuticals are food components or active ingredients present in foods and used in therapy. This article analyzes the characteristics of the molecules with a lipid-lowering effect. The different nutraceuticals may have different mechanisms of action: inhibition of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase (policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols, probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul). Based on the different mechanisms of action, some nutraceuticals are then abl…

lcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaCombination therapyPharmacologyCardiovascular Medicinelipidschemistry.chemical_compoundNutraceuticalBerberinelipidRed yeast riceReviews in MedicineMedicineLDL-cholesterolPolicosanolActive ingredientnutraceuticalsbusiness.industrycardiovascular preventionClinical trialchemistrylcsh:RC666-701Intestinal cholesterol absorptionhypolipidemic therapynutraceuticalCardiology and Cardiovascular Medicinebusinessmedicine.drugFrontiers in cardiovascular medicine
researchProduct

PCV71 Sponsorship and Pharmacoeconomic Conclusions of Studies on Statin Use for Cardiovascular Prevention: A Systematic Analysis

2011

medicine.medical_specialtyCardiovascular preventionbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthmedicineAlternative medicineStatin treatmentIntensive care medicinebusinessValue in Health
researchProduct

El papel de la dislipemia aterogénica en las guías de práctica clínica.

2016

Background and objective Atherogenic dyslipidaemia is underdiagnosed, undertreated, and under-controlled. The aim of the present study was to assess the positioning of clinical guidelines as regards atherogenic dyslipidaemia. Material and method The major clinical guidelines of scientific societies or official agencies issued between January 1, 2012 and March 31, 2015 were collected from the MEDLINE database. High-density lipoprotein (HDL) cholesterol, triglycerides, atherogenic dyslipidaemia, non-HDL cholesterol, and apolipoprotein (apo) B were gathered from the 10 selected guidelines, and it was assessed whether these parameters were considered a cardiovascular risk factor, a therapeutic …

medicine.medical_specialtyLow HDL-cholesterolendocrine system diseasesApolipoprotein BNice030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCardiovascular preventionInternal medicinemental disordersmedicinePharmacology (medical)cardiovascular diseases030212 general & internal medicineRisk factorcomputer.programming_languagebiologybusiness.industryCholesterolnutritional and metabolic diseasesClinical Practicechemistrybiology.proteinlipids (amino acids peptides and proteins)Atherogenic dyslipidaemia Cardiovascular prevention Cholesterol Colesterol Dislipemia aterogénica Guías de práctica clínica Lipids Lípidos Practice guidelines Prevención cardiovascular Triglicéridos TriglyceridesCardiology and Cardiovascular MedicinebusinesscomputerLipoprotein
researchProduct

Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study

2021

The Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension conceived and designed an ad hoc study aimed at searching for prognostic cut-off values of serum uric acid (SUA) in predicting combined (fatal and non-fatal) cerebrovascular (CBV) events in the whole database. The URic acid Right for heArt Health study is a nationwide, multicenter, observational cohort study involving data on subjects aged 18-95 years recruited on a regional community basis from all the territory of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 120.7 ± 61.8 months. A total of 14,588 subjects were included in the analysis. A prognos…

medicine.medical_specialtySettore MED/09 - Medicina Internauric acid cardiovascular riskserum uric acid; stroke; hypertension; cardiovascular prevention; cardiovascular diseasechemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansStrokeuric acid hypertensionbusiness.industryConfoundingPrognosismedicine.diseaseConfidence intervalUric AcidStrokechemistryHypertensionUric acidbusinessBody mass indexCohort studyKidney disease
researchProduct

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

2005

The term "lipid triad" or "atherogenic lipoprotein phenotype" has been introduced to describe a common form of dyslipidemia, characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol concentrations and the presence of small, dense LDL particles. It has been suggested that the clinical importance of the atherogenic lipoprotein phenotype probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait than hypercholesterolaemia. There is a body of evidence that therapies effective against plasma HDL-cholesterol and triglycerides are associated with a strong reduction of cardiovascul…

medicine.medical_specialtySmall dense ldlBiologyCoronary artery diseaseCardiovascular preventionInternal medicineInternal MedicinemedicineHumansNational Cholesterol Education ProgramDyslipidemiasHypolipidemic AgentsLDL HDL triglycerides preventionBiochemistry (medical)LDL Particle SizeTriad (anatomy)Atherogenic lipoprotein phenotypemedicine.diseaseAtherosclerosisLipoproteins LDLEndocrinologymedicine.anatomical_structureCardiovascular Diseaseslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineDyslipidemiaJournal of atherosclerosis and thrombosis
researchProduct